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Abstract
Background—Uveal melanoma exhibits a high incidence of metastases and no systemic therapy
clearly improves outcomes. The anti-CTLA-4 antibody ipilimumab is a standard of care for
metastatic melanoma; however, the clinical activity of CTLA-4 inhibition in patients with
metastatic uveal melanoma is poorly defined.
Methods—To assess ipilimumab in this setting, we performed a multicenter, retrospective
analysis of four hospitals in the United States and Europe. Clinical characteristics, toxicities and
radiographic disease burden as determined by central, blinded radiology review were determined.
Results—Thirty-nine patients were identified (34 treated with 3 mg/kg and 5 treated with 10 mg/
kg). Using the immune-related response criteria and modified WHO criteria, response rate (RR)
and combined response plus stable disease (SD) rate were assessed after 12 weeks, 23 weeks and
total (median follow-up 50.4 weeks (12.6 months)). At week 12, the RR and response plus SD rate
were 2.6% and 46.0%, at week 23: 2.6% and 28.2%. There was one complete response and one
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late partial response (at 100 weeks after initial SD) for irRR of 5.1%. Immune-related adverse
events (irAE) were observed in 28 (71.8%) patients, with seven (17.9%) grade 3-4 events. irAEs
were more frequent in patients receiving 10 mg/kg versus 3 mg/kg. The median overall survival
from first dose of ipilimumab was 9.6 months (confidence interval 6.3-13.4 months, range:
1.6-41.6 months). Performance status, LDH and absolute lymphocyte count ≥1000 cells/μL at
week 7 were significantly associated with survival.
Conclusions—In uveal melanoma, durable responses to ipilimumab and manageable toxicity
were observed.
Keywords
uveal melanoma; ipilimumab; CTLA-4; immunotherapy; absolute lymphocyte count
Introduction
Uveal melanoma is a rare form of melanoma that represents about 3-5% of the incidence of
cutaneous melanomas.1 Metastasis in uveal melanoma is common with approximately 50%
of patients developing distant cancer within 15 years of initial diagnosis.2 Uveal melanoma
harbors a unique set of genetic alterations compared with cutaneous melanoma. Whereas
cutaneous melanoma often harbors activating mutations in BRAF and NRAS, mutations in
the heterotrimeric G protein alpha-subunits, GNAQ and GNA11, have been reported in
approximately 80% of uveal melanomas.3 GNAQ and GNA11 mutations are not, however,
correlated with disease free survival or the development of metastasis.4
The outcome for patients with metastatic uveal melanoma is dismal, with a median survival
of approximately 12 months,5 and no systemic therapy has improved survival.6 Drugs
commonly used to treat advanced cutaneous melanoma rarely achieve durable responses in
patients with uveal melanoma. Treatment with dacarbazine (DTIC), carmustine (BCNU),
cisplatin, and tamoxifen (Dartmouth regimen) was reported to show a response rate of 6%
and a phase II study of carboplatin, paclitaxel and sorafenib described no objective
responses7, 8. A retrospective review of 143 patients treated with chemotherapy at MD
Anderson Cancer Center reported a single objective response and other reviews of the
Eastern Cooperative Oncology Group (ECOG) and Southwestern Oncology Group
described similar findings.9, 10
Immunotherapy for the treatment of metastatic uveal melanoma has also conceptually been
of interest. It is hypothesized that uveal melanoma may be more immunogenic than other
tumors since it arises in the immunologically privileged site of the eye. Further, uveal
melanoma has high expression of multiple cancer antigens known to be immunogenic,
including gp100, MAGE, MART-1, tyrosinase and TRP-1.11, 12 Clinical experience with
immunotherapy in uveal melanoma is limited with case reports describing success; however,
larger series showed equivocal benefit.13, 14
Ipilimumab (Bristol-Myers Squibb, Princeton, NJ) is a fully human monoclonal antibody
that augments anti-tumor immunity through blockade of cytotoxic T lymphocyte antigen-4.
Ipilimumab has become a standard of care for the treatment of patients with metastatic
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melanoma after an overall survival benefit was demonstrated.15 The activity of ipilimumab
in uveal melanoma, however, has not been well described. A retrospective series of 13
patients with metastatic uveal melanoma treated with ipilimumab reported three patients
with stable disease as the best response,16 and a smaller review described two out of five
patients with stable disease at 11 months.17 Only preliminary data describing patients with
uveal melanoma treated with ipilimumab in expanded access programs have been
presented.18 Given the limited therapeutic options available to patients with uveal
melanoma, determining the efficacy of ipilimumab in uveal melanoma is essential.
We conducted a multicenter, retrospective analysis of 39 patients with metastatic uveal
melanoma treated with ipilimumab under an expanded access clinical program or using
commercial drug. We report the clinical activity and toxicity observed from four academic
hospitals in the United States and Europe.
Methods
Patients and Clinical Characteristics
After obtaining institutional review board approval at each site, patients with metastatic
uveal melanoma treated with ipilimumab were identified from the databases of four
institutions (Dana-Farber Cancer Institute, Massachusetts General Hospital, Memorial
Sloan-Kettering Cancer Center, United States and University Hospital of Lausanne,
Switzerland). Patients treated on clinical protocols and with commercial drug were included.
Patients receiving ipilimumab in combination with other agents or as re-induction therapy
were excluded. Relevant clinical parameters were collected including age, gender, ECOG
performance status, site(s) of metastatic disease, lines of prior therapy as well as dose of
ipilimumab received. Laboratory parameters were collected including lactate dehydrogenase
(LDH) at time of first ipilimumab infusion, and absolute lymphocyte count (ALC) before
treatment as well as at approximately seven weeks after initiation of therapy. Treatment
response and safety data were also determined. All data was aggregated following patient
de-identification.
Efficacy and Toxicity Assessment
Efficacy outcomes were determined by a radiologist at each site who was blinded to
outcome. Beneficial effects of ipilimumab were categorized as complete response (CR),
partial response (PR) or stable disease (SD). Response plus SD rate was calculated as the
percentage of patients achieving a CR, PR or SD at 12 weeks, 23 weeks or longer after
starting ipilimumab treatment. The immune-related response criteria (irRC) and modified
World Health Organization (mWHO) criteria were applied to determine each patient's
response.19 Overall survival (OS) was calculated by Kaplan-Meier methodology from first
dose of ipilimumab to date of death by any cause. Toxicity was assessed through chart
review and graded using Common Terminology Criteria for Adverse Events (version 4.0).
Special attention was given to events of special interest or immune-related adverse events
(irAE) including rash, colitis, hepatitis, thyroiditis and hypophysitis.
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Univariate comparisons of OS for ipilimumab dose (10 mg/kg or 3 mg/kg), baseline LDH,
ECOG performance status, and ALC were conducted using Kaplan-Meier estimates;
differences were assessed using the log-rank test. LDH was divided as above or below the
institutional upper limit of normal; ALC was divided into low (<1000 cells/μL) or normal
(≥1000 cells/μL). ECOG performance status was classified as fully active versus any
restriction (0 versus 1-2). Statistically significant predictors in the univariate comparisons
were then included in a multivariable Cox proportional hazards regression model. The Cox
regression was stratified by number of prior therapies (treatment-naive versus other) to
allow for underlying differences in the baseline hazards of death between these two groups.
Landmark analyses were conducted to compare OS between 7-week ALC levels (low versus
normal) as this has been suggested as a biomarker of ipilimumab efficacy in cutaneous
melanoma.20, 21 Comparisons of rates of adverse events were based on Fisher's exact test.
Statistical significance was defined as p < 0.05.
Results
Patient and Clinical Characteristics
The clinical characteristics of the thirty-nine patients included in the analysis are shown in
Table 1. Patients were predominately male with a median age of 61 years and median
ECOG status of 0. The median number of prior therapies was one with approximately half
of patients being treated as part of the Bristol-Myers Squibb expanded access clinical
protocol (CA184045). Five patients (13%) received ipilimumab at 10 mg/kg while others
received 3 mg/kg. The median number of ipilimumab doses was four (range 1-16). Three
patients received maintenance dosing.
Response Analysis
Of the 39 total patients identified, 35 were evaluable for radiographic assessment of changes
in tumor burden following ipilimumab. The four patients who were not assessable either
died prior to assessment of change in tumor burden or were transitioned to palliative care
only without subsequent imaging. These patients were assumed to have had progressive
disease and were included in all analyses.
Given that tumor assessments were performed both on and off protocol, the timing of
restaging radiography was somewhat variable in the study population. With that caveat, it
was observed that the first through fourth scans took place at medians of 10.7, 16.1, 23.0 and
31.3 weeks. When adjusting for the twelve patients who were restaged prior to completing
ipilimumab induction (prior to 10 weeks), the median time to first scan was 12.0 weeks. In
the twelve patients who had early restaging performed, the median time to first scan was 6.2
weeks.
By irRC, at the time of the first radiographic assessment (approximately week 12) there
were one irCR and 17 irSD. The irCR was confirmed on subsequent scans, and, notably, one
patient who had irSD at week 12 and week 23 developed a late response, achieving irPR at
approximately week 100. Prior to week 23, six irSD had progressive disease (PD). One irSD
had a confirmatory scan for SD but was not yet evaluable at 23 weeks. Additionally, three
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patients who had irSD at week 12 and 23 later had PD (at weeks 28, 31 and 33). Data on
response and response plus SD rate are listed in Table 2A. In evaluation of the total study
cohort (median follow-up of 50.4 weeks (12.6 months)), there was one irCR, one irPR and
six irSD. Seventeen patients had PD at the time of the first scan; however, only seven of
these patients had the required follow-up scan documenting progression, as required by
irRC. The response rate in total follow up by irRC was 5.1% (2/39).
By the mWHO criteria, at first radiographic assessment (week 12), one CR and fifteen SD
were observed. Seventeen patients had PD at the time of the first scan. Two patients
classified as SD by the irRC were reclassified as having PD by mWHO given the
appearance of new lesions. One patient was initially classified as having SD but entered
greater than 50% tumor reduction at approximately week 100. In evaluation of the total
study cohort at last follow-up, the overall response rate by mWHO was identical to the
response rate by the irRC (5.1%, 2/39 patients).
The changes in disease burden from baseline by individual patient are shown in Figure 1.
The patient who achieved a CR by both irRC and mWHO was treated with ipilimumab at 3
mg/kg and has had a durable response currently ongoing at 62 weeks. This patient had
received treatment with temozolomide chemotherapy prior to ipilimumab and experienced
grade 1 rash during treatment. Sites of responding disease in this patient included liver, soft
tissue and skin metastases. The patient who achieved mWHO SD but late irPR by irRC was
previously treated with selumetinib and pegylated arginine deiminase. This response is on-
going at 140 weeks. This patient had late toxicity with the development of grade 4 uveitis
approximately 2.5 years following the initiation of ipilimumab. Sites of responding disease
included brain and soft tissue metastases. Another notable patient achieved irSD though had
significant tumor shrinkage through both 12 and 23 weeks. This patient was previously
treated with temozolomide and everolimus and the response to ipilimumab is on-going at
30.4 weeks. Sites of responding disease in this patient included liver and lung metastases.
Further clinical details for patients with response or stable disease at 23 weeks are described
in Table 2B.
The biochemical parameters of patients experiencing response or SD at at last follow up
included LDH level that was within normal limits in all but three patients, with two of those
being just slightly out of range. All patients experiencing experiencing response or SD at last
follow up had a rise in ALC from baseline to week 7 (median increase of 600 cells/μL),
except for one patient who had a very slight decrease of 300 cells/μL. Half of patients
obtaining response or SD at last follow up experienced irAE including two patients with
irSD who experienced grade 3 hepatitis and grade 4 hypophysitis, respectively.
Overall Survival Analysis
After a median follow-up of 12.6 months for survivors, the median overall survival by
Kaplan-Meier methodology for the entire cohort was 9.6 months, with a 95% confidence
interval (CI) of 6.3 to 13.4 months (Figure 2). In univariate analysis, neither dose of
ipilimumab (3 mg/kg vs. 10 mg/kg) nor baseline ALC (low vs. normal) was significantly
associated with survival (log-rank p=0.41 and 0.10, respectively). However, ECOG
performance status (0 vs 1-2, log-rank p < 0.0001), lines of prior treatment (0 vs any, log-
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rank p = 0.04) and LDH within normal limits (normal vs. elevated, log-rank p=0.005) were
associated with improved survival. The median length of time between diagnosis of
metastatic cancer and first dose of ipilimumab was 12.1 months (range 0.6 to 47 months).
Based on a multivariable Cox proportional hazard model of overall survival with ECOG
status and LDH class as covariates, ECOG status of 0 demonstrated an 87% reduction in the
hazard of death compared with ECOG 1-2 (hazard ratio (HR): 0.13, 95% CI (0.04 to 0.44),
p=0.001) and LDH within institutional normal limits showed an 82% reduction in the hazard
of death (HR: 0.18, 95% CI (0.05 to 0.73), p=0.02).
A landmark analysis of week 7 ALC indicated statistically significant differences in OS
between normal and low ALC levels (Figure 3). For the 31 patients who were alive and had
ALC measurements at week 7, ALC ≥1000 cells/μL (n = 22) was associated with a median
OS of 13.4 months, 95% CI (9.6 to ∞) compared with a median of 4.8 months, 95% CI (3.6
to 7.0) in patients with ALC < 1000 cells/μL (n=9) (log-rank p=0.004). All patients with SD,
PR or CR at 23 weeks had ALC ≥1000 cells/μL at week 7. The landmark analysis excluded
six patients with survival times less than seven weeks and two additional patients with ALC
missing at week 7.
Toxicity Analysis
The overall incidence of irAE was 71.8% (Table 3). Rash was the most common irAE,
affecting eleven patients. Two patients had diarrhea and in both cases, grade 3 colitis was
confirmed via colonoscopy. These patients were treated with intravenous corticosteroids
followed by slow steroid taper with rapid resolution of diarrhea. There were four patients
reported to have thyroiditis (grade 1), one patient each with hepatitis and pancreatitis (both
grade 3) and two patients reported to have hypophysitis (both grade 3). One patient
experienced grade 4 uveitis. Patients with grade 3-4 liver and pancreatic toxicities received
prompt corticosteroid intervention with resolution of symptoms in all cases without
recurrence after steroid taper. Some patients required systemic steroids for management of
irAEs. Two patients with thyroiditis and both patients with hypophysitis required on-going
hormone replacement after ipilimumab treatment. The patient with uveitis had significant
vision loss impacting her activities of daily living that has persisted despite attempted
corticosteroid pulse and taper. Though numbers were small, the overall incidence of
immune-related toxicities was greater in patients receiving 10 mg/kg vs. 3 mg/kg: 67.6% (23
of 34) of patients receiving 3 mg/kg had irAEs of any grade compared with 100% of patients
at 10 mg/kg (5 of 5). However, the comparison was not statistically significant (Fisher's
exact p-value = 0.30). The rates of grade 3-4 events were higher, though not statistically
significant, in the 10 mg/kg group (2 of 5, 40%) compared with the 3 mg/kg group (5 of 34,
14.7%) (Fisher's exact p-value = 0.21).
Discussion
Our retrospective study evaluating the activity of ipilimumab in 39 patients from four
academic centers in the United States and Europe is the largest report to date of the activity
of ipilimumab in uveal melanoma and provides the first evidence that ipilimumab can
generate mWHO and irRC responses, as well as stable disease, in patients with metastatic
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uveal melanoma. The response rate at last follow up in our study was 5.1%. This is similar
to the reported response rates for ipilimumab in cutaneous melanoma of 4.2-10.9% and is
higher than any published therapy specifically for uveal melanoma.15, 22, 23 The median
overall survival by Kaplan-Meier methodology in our study was 9.6 months. Several
patients had on-going on-going stable disease at the time of the analysis, with two patients
having durable responses of >60 weeks. These durable responses underscore the potential
utility of immune-check point blockade for the treatment of patients with metastatic uveal
melanoma.
The toxicity of ipilimumab in our series also suggests that it can be given safely in this
patient population. Previous descriptions of grade 3-4 toxicities with ipilimumab have
reported rates around 10%.18 The grade 3-4 toxicity rate in this study is higher, at 17.9%;
however this appears to have been weighted by those patients who received 10 mg/kg of
ipilimumab. Importantly, all grade 3-4 irAEs, with the exception of uveitis in a patient who
had been treated for over two years, resolved with prompt initiation of high-dose
corticosteroids followed by a slow steroid taper. This is similar to what has been described
in the management of irAE in cutaneous melanoma and underscores the need for vigilance
by the treating physician regarding these potential events.
There have been many studies published on various treatment regimens for metastatic uveal
melanoma though no clear standard therapy exists. Multiple reviews of chemotherapy have
described response rates in the single digits.9, 10 Biochemotherapy, generally combining
cisplatin, vinblastine, dacarbazine with interleukin-2 and interferon-α, has been advocated in
retrospective analysis to be associated with improved survival however the treatment is
associated with significant toxicity which many patients will be unable to tolerate.24
More recently, there has been a focus on the emerging molecular biology of uveal
melanoma. Preliminary efficacy has been reported for an ongoing randomized phase II study
of selumetinib versus temozolomide, with responses observed in 4 of 21 (19%) patients
treated with the MEK inhibitor.25 However, in the phase I study of the MEK inhibitor
trametinib, eight of 16 patients with uveal melanoma met criteria for SD though no
responses were seen and the median progression free survival was only 1.8 months.26 In a
phase II trial of the VEGF-trap, aflibercept, five of 10 patients with uveal melanoma were
noted to be progression free at 4 months, though there were no responses seen.27
While several of these molecularly targeted approaches are promising, durable benefit
remains elusive. In our study of ipilimumab, two patients (5.1%) had responses and nine
(23.1%) had SD lasting beyond 33 weeks by irRC and mWHO. This is similar to what has
been described for ipilimumab in cutaneous melanoma where a “tail on the curve”
phenomenon indicates that some patients have durable clinical benefit over years.28 Even
removing the potential for long term benefit however, we observed three and six month
stable disease rates of 46.1% and 28.2%. Prior experiences with DTIC and temozolomide in
metastatic uveal melanoma have reported median progression times of approximately 1.5
months, and a progression-free survival of four months has been proposed as a significant
improvement in stable disease for uveal melanoma in clinical trials (ClinicalTrials.gov
Identifier: NCT01143402). Though our data is limited by its retrospective nature,
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ipilimumab seems to compare favorably to other published systemic therapies for patients
with metastatic uveal melanoma.
Our data also suggest that the timing for use of ipilimumab may be important as well.
Though sample sizes are small, we observed significant associations between both ECOG
performance status and LDH with survival from the time of ipilimumab treatment. This
suggests that the maximum benefit from ipilimumab is likely to come early in the treatment
course of these patients, prior to acceleration of cancer growth and decline in functional
status. Early treatment is also reinforced by the possibility for late immune induction with
anti-tumor effect. Though we did not observe a patient who met criteria for progression with
subsequent response, we did observe a patient with SD who eventually developed a PR.
Allowing time for late induction of an immune-related anti-tumor effect can be difficult and
this emphasizes the importance of performance status in consideration of ipilimumab
treatment.
It has been suggested that rise in ALC during ipilimumab treatment may associated with
clinical benefit and overall survival.20 We noted ten of eleven patients obtaining response or
SD at last follow up had a rise in ALC and that ALC ≥1000 cells/μL at week 7 significantly
stratified patients by median overall survival (13.4 versus 4.8 months, log-rank p = 0.004).
All patients experiencing response or SD at last follow up had ALC ≥1200 cells/μL at 7
weeks. These data recommend ALC at week 7 for further study as a biomarker of activity
for ipilimumab in uveal melanoma. Given the aggressiveness of this disease, the potential
for an early biomarker of treatment efficacy would be very useful in the clinical
management uveal melanoma.
Our investigation is limited by several factors. Toxicities were captured by chart review and
thus may have led to a bias toward under-reporting, though the fact that just over half of the
patients were treated on a clinical protocol may help to alleviate this to some degree.
Additionally, though the databases of four melanoma referral centers were utilized, the study
sample size of 39 patients is relatively small. As such, the data may be subject to variability
with obfuscation of significant differences that might exist among different patient sub-sets.
Finally, our cohort was heterogeneous with patients treated on protocol and off, in various
lines of therapy and with different doses of ipilimumab.
Despite these limitations, this investigation represents a robust evaluation of the clinical
experience with ipilimumab in patients with metastatic uveal melanoma and is the first to
report responses to ipilimumab in patients with uveal melanoma. A further strength of this
report is that approximately half of our patients were treated off protocol in a standard
clinical practice setting, as compared with prior reports where patients were restricted to an
expanded access program (ClinicalTrials.gov Identifier: NCT00495066). Further, by
drawing on the experience from four academic centers, we may have minimized institutional
biases that might be present within a single center.
It appears that further exploration of the molecular biology of uveal melanoma will lead to
novel targeted therapeutic strategies; however, our data suggest that ipilimumab is a
treatment that can induce responses or stable disease for some patients and is already
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available in standard practice. The toxicity we observed was manageable and not
significantly different than that seen in the treatment of metastatic cutaneous melanoma.
Prospective studies of ipilimumab in metastatic uveal melanoma are on-going to better
delineate the exact clinical utility of this agent. Based on our data, we would suggest that
ipilimumab be considered a reasonable therapeutic choice for this patient population.
Patients with uveal melanoma should be included in future clinical studies evaluating novel
immunotherapeutic approaches.
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Figure 1. Change in disease burden for each patient over time
Star indicates that patient 27 experienced initial irSD, entering irPR at approximately week
100 with on-going response at week 140 and patient 21 experienced irCR that is on-going at
week 62.
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Figure 2. Overall survival for entire cohort
The median overall survival for the total cohort was 9.6 months, 95% CI (6.3 to 13.4
months).
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Figure 3. Overall survival stratified by ALC at seven weeks
ALC ≥ 1 (Solid Line): median overall survival of 13.4 months, 95% CI (9.6 to ∞), ALC < 1
(Dotted Line): median overall survival of 4.8 months, 95% CI (3.6 to 7.0).
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